Literature DB >> 29408492

Transcriptomic analyses of chemokines reveal that down-regulation of XCR1 is associated with advanced hepatocellular carcinoma.

Wang Yanru1, Bai Zhenyu2, Niu Zhengchuan3, Qi Qi4, Liang Chunmin5, Yao Weiqiang6.   

Abstract

Chemokines are essential coordinators of cellular migration and cell-cell interactions, therefore considerable attention has been paid to the application of chemokines to cancer immunotherapy. In this study, we screened for the expression levels of 58 human chemokines/chemokine receptors in hepatocellular carcinoma (HCC) by using samples from the TCGA LIHC cohort and found 16 consistently down-regulated and 11 up-regulated chemokine genes in HCC compared with normal samples. Furthermore, the expressions of XCR1 were verified by Western blot in liver cancer cell lines. We used CCK8, plate cloning formation, scratch-wound and transwell analysis to measure the ability of proliferation, metastasis and invasion, respectively. Protein expression was analyzed by cell immunofluorescence and western-blot. We found that silencing XCR1 promoted, while overexpressing XCR1 inhibited, HCC cell migration and invasion in vitro, its mechanism may involve in inhibition of Epithelial Mesenchymal Transition (EMT). However, the overexpression of XCR1 in HCCLM3 in vitro can restrain the growth partially due to the inhibition of MAPK and PI3K/AKT signaling pathway. Gene Set Enrichment Analysis (GSEA) showed that high expression of XCR1 is positively associated with EMT, which is closely associated with tumor migration and invasion. Our study provides the basis for further investigation of the molecular mechanism by which down-regulation of XCR1 promotes the development and progression of HCC.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Function analysis; Liver cancer; Proliferation; XCR1

Mesh:

Substances:

Year:  2018        PMID: 29408492     DOI: 10.1016/j.bbrc.2018.02.008

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Construction of a 13-Gene Signature as a Novel Prognostic Marker for Patients with Clear Cell Renal Cell Carcinoma and the Role of XCR1 in Cell Proliferation.

Authors:  Baoying Yuan; Feifei Li; Youbao Li; Yuhan Chen
Journal:  Cancer Manag Res       Date:  2020-05-27       Impact factor: 3.989

Review 2.  Emerging Roles of G Protein-Coupled Receptors in Hepatocellular Carcinoma.

Authors:  Wen-Ting Peng; Wu-Yi Sun; Xin-Ran Li; Jia-Chang Sun; Jia-Jia Du; Wei Wei
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

3.  Fifteen mRNA-lncRNA expression-based signature predicted the survival of late-staged head and neck squamous cell carcinoma.

Authors:  He Ren; Huaping Li; Ping Li; Yuhui Xu; Gang Liu; Liping Sun
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

4.  Elevated nuclear auto-antigenic sperm protein promotes melanoma progression by inducing cell proliferation.

Authors:  Jia-Xia Li; Chuan-Yuan Wei; Shu-Gang Cao; Ming-Wu Xia
Journal:  Onco Targets Ther       Date:  2019-03-21       Impact factor: 4.147

Review 5.  Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside.

Authors:  Gabriel Siracusano; Mariella Tagliamonte; Luigi Buonaguro; Lucia Lopalco
Journal:  Vaccines (Basel)       Date:  2020-01-24

6.  CCL14 serves as a novel prognostic factor and tumor suppressor of HCC by modulating cell cycle and promoting apoptosis.

Authors:  Mengxuan Zhu; Weiyue Xu; Chuanyuan Wei; Jing Huang; Jietian Xu; Yuye Zhang; Yan Zhao; Jie Chen; Shuangshuang Dong; Binbin Liu; Chunmin Liang
Journal:  Cell Death Dis       Date:  2019-10-22       Impact factor: 8.469

7.  Overexpression of chemokine receptor lymphotactin receptor 1 has prognostic value in clear cell renal cell carcinoma.

Authors:  Xian Chang; Ya Cao; Wan-Lei Fu; Xue-Feng Tang; Ya-Li Wang; Yang-Fan Lv; Qiao-Nan Guo
Journal:  Mol Genet Genomic Med       Date:  2020-12-30       Impact factor: 2.183

8.  Role of chemokines in hepatocellular carcinoma (Review).

Authors:  Dongdong Xue; Ya Zheng; Junye Wen; Jingzhao Han; Hongfang Tuo; Yifan Liu; Yanhui Peng
Journal:  Oncol Rep       Date:  2020-12-22       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.